Han Charles C, Prasetyo Davin, Wright Gavin M
Department of Surgical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia.
J Thorac Oncol. 2007 Jan;2(1):59-64. doi: 10.1097/JTO.0b013e31802bff2d.
Endobronchial neodymium:yttrium aluminum garnet (Nd:YAG) laser therapy has been shown to be safe and effective in palliating large airway malignancies. The role of multimodal therapy with stenting, brachytherapy, chemotherapy, and radiotherapy together with Nd:YAG laser therapy is unclear.
This study aims to confirm the safety and effectiveness of Nd:YAG laser therapy in the contemporary setting and to investigate the effectiveness of multimodal therapy compared with laser alone.
One hundred fifty-three Nd:YAG laser treatments on 110 patients between 1999 and 2004 were reviewed retrospectively. Symptom scores for dyspnoea, hemoptysis, and cough before and after the procedure were compared. Survival and time to reintervention were analyzed using the Kaplan-Meier method. Multimodality treatment was compared with Nd:YAG laser therapy alone to determine differences in survival and time to reintervention. p values less than 0.05 were considered significant.
There were no operative mortalities directly caused by laser intervention, although 30-day mortality was 6.5%. Deaths were attributable to progression of advanced neoplastic processes rather than laser intervention, and 6.5% of patients had some postoperative morbidity. After Nd:YAG laser intervention, 76% of patients reported improvement to dyspnoea, 94% for hemoptysis, and 75% for cough. Median survival after Nd:YAG laser treatment was 6.64 months; 21% of patients required repeated laser treatment. Compared with Nd:YAG laser treatment alone, multimodality treatments significantly prolonged median time to reintervention by 1.7 months (p = 0.002) and prolonged median survival by 4.9 months (p < 0.001) in patients with NSCLC.
Nd:YAG laser intervention is safe and effective for palliation of endobronchial malignancies. In most cases, it only needs to be performed once. Compared with Nd:YAG laser therapy alone, multimodal treatment prolonged survival.
支气管内钕钇铝石榴石(Nd:YAG)激光治疗已被证明在缓解大气道恶性肿瘤方面是安全有效的。支架置入、近距离放射治疗、化疗和放疗与Nd:YAG激光治疗联合的多模式治疗的作用尚不清楚。
本研究旨在证实Nd:YAG激光治疗在当代环境中的安全性和有效性,并研究多模式治疗与单纯激光治疗相比的有效性。
回顾性分析了1999年至2004年间对110例患者进行的153次Nd:YAG激光治疗。比较了治疗前后呼吸困难、咯血和咳嗽的症状评分。采用Kaplan-Meier方法分析生存情况和再次干预时间。将多模式治疗与单纯Nd:YAG激光治疗进行比较,以确定生存情况和再次干预时间的差异。p值小于0.05被认为具有统计学意义。
尽管30天死亡率为6.5%,但没有直接由激光干预导致的手术死亡。死亡归因于晚期肿瘤进展而非激光干预,6.5%的患者有一些术后并发症。Nd:YAG激光干预后,76%的患者报告呼吸困难有所改善,咯血改善率为94%,咳嗽改善率为75%。Nd:YAG激光治疗后的中位生存期为6.64个月;21%的患者需要重复激光治疗。与单纯Nd:YAG激光治疗相比,多模式治疗显著延长了非小细胞肺癌患者再次干预的中位时间1.7个月(p = 0.002),并将中位生存期延长了4.9个月(p < 0.001)。
Nd:YAG激光干预对于缓解支气管内恶性肿瘤是安全有效的。在大多数情况下,仅需进行一次。与单纯Nd:YAG激光治疗相比,多模式治疗延长了生存期。